HHS CEOs
Directors of Medical Services
Directors of Pharmacy
Chairs, Medicines Advisory Committees
QHPIMS-Support Unit
Dispensary Managers
QHMAC Members
Central Pharmacy (Graham Cook, Robin Lee, Nicole Zischke, Sam Webb)
CIRCS (Maree Bransdon)
Stephanie Boydell, Acting Executive
Secretary Queensland Health
Medicines Advisory Committee
3131 6516
3131 6568
Summary of changes to the Queensland Health List of Approved Medicines
(LAM) as a result of the March 2014 Queensland Health Medicines Advisory
Committee (QHMAC) meeting
CASS/000942
1403adv
At the March 2014 meeting the Queensland Health Medicines Advisory Committee (QHMAC) recommended the following changes to the List of Approved Medicines (LAM). These have been approved by the Committee Sponsor, Chief Executive, Health Services Support Agency (HSSA) and will be effective from 1 June 2014 - or as otherwise stated in the attached.
There are six editions of the LAM each year. These current changes will be included in the
1 June 2014 edition of the LAM which will be published on QHEPS at http://qheps.health.qld.gov.au/hssa/medicines/lam/home.htm
.
Please distribute this document as deemed appropriate to relevant clinicians. For future reference, monthly
Summary of Changes can be found unde r “QHMAC meeting outcomes” at http://qheps.health.qld.gov.au/hssa/medicines/committees/qhmac/outcomes.htm
Note: These amendments may also include a number of items which are planned for earlier inclusion in the
LAM – such as medicines which are available under the Highly Specialised Drugs Program or for which
QHMAC specifically endorsed an earlier inclusion date.
Signed
Stephanie Boydell
Acting Executive Secretary
Queensland Health Medicines Advisory Committee
02 / 05 / 2014

Item number
Medicine Decision and date effective
Restriction
14/018 Chlorhexidine, alcoholic solution red 2% in alcohol 70%, 100mL
14/018A Chlorhexidine, alcoholic solution pink 2% in alcohol 70%, 100mL
14/014 Denosumab injection, prefilled syringe
60mg in 1mL
Added
01-Jun-14
Added
01-Jun-14
Added
01-Jun-14
14/007 Fat emulsion - soya oil,
MCT, olive oil, fish oil
"SMOFlipid" IV infusion
20%, 100mL
Added
01-Jun-14
14/010 Ivabradine tablet 7.5mg Added
01-Jun-14
14/009A Pazopanib tablet
200mg, 400mg
Added
01-Jun-14
13/103B Esomeprazole tablet
20mg (Pack of 7 only)
14/010 Ivabradine tablet 5mg
Amended
01-Jun-14
Amended
01-Jun-14
13/103 Omeprazole suspension
2mg per mL, 100mL
13/103A Omeprazole tablet
(omeprazole magnesium)
10mg, 20mg
Amended
01-Jun-14
Amended
01-Jun-14
For discharge and outpatient use as per the PBS indications.
‘Specialist Staff for use in neonates for prolonged intravenous therapy when oral or enteral feeding is not possible’
Specialist Staff for use in chronic heart failure, as per the PBS indications
Specialist Staff for discharge and outpatient use in patients with stage IV clear cell renal cell carcinoma, as per the PBS indications
Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.
Cardiologists and Radiologists to reduce heart rate in patients in sinus rhythm undergoing CT coronary angiography who do not respond to maximal doses of betablockers or are unable to tolerate beta blockers (or when a beta blocker is contraindicated).Specialist Staff for use in chronic heart failure, as per the PBS indications
Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.
[Note: This restriction now includes use in neonates and infants, in addition to tube administration in patients up 18 years of age.]
Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.
Page 2 of 4

Item number
Medicine
13/103C Pantoprazole tablet
20mg, 40mg
14/016 Alfentanil injection
1mg In 2mL
14/015 Hydromorphone hydrochloride injection
2mg in 1mL
14/003 Reactivated Item –
Fondaparinux sodium injection pfs
2.5mg in 0.5mL
14/008 Vaccines for stem cell transplant recipients
14/012 Aprepitant, pack - 1 capsule
125mg and 2 capsules
Decision and date effective
Amended
01-Jun-14
Deferred
Deferred
Deferred
Deferred
Deleted
01-Jan-14
14/011A
1
80mg
Ganciclovir intravitreal implant 4.5mg
Deleted
01-Jan-14
14/017A Raloxifene tablet 60mg Deleted
01-Aug-14
14/017 Strontium ranelate sachet containing
Deleted
01-Jun-14 granules for oral suspension 2g (28)
Not Added 13/105 Sodium chloride 0.9% prefilled syringe 10mL
(BD Posiflush ® )
Noted 13/102A Amphotericin: injection
50mg, lipid complex injection 100mg in
20mL, liposomal injection 50mg
13/101A Dalteparin sodium Noted
Restriction
Specialist Staff and Country Medical Superintendents for use in line with the proton pump inhibitor flowchart at Appendix 4.
Reviewing Individual Patient Approval (IPA) guideline for use in VTE prophylaxis.
[Note: this item will be further considered at the May 2014 meeting.]
Page 3 of 4

Item number
Medicine Decision and date effective
14/011A
2 injection, prefilled syringe
2,500 IU in 0.2mL;
5,000 IU in 0.2mL
Disodium pamidronate injection 15mg
13/103D Omeprazole capsule
20mg
14/013 For information - review of the LAM
Noted
Noted
Noted
Restriction
Page 4 of 4